The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial
Open accessAbstract
An oral small molecule turns on the transcription of human interleukin-12, with biological effects in patients with recurrent high-grade gliomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Interleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
Self-citationBevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Self-citationGlioblastoma and Other Malignant Gliomas: A Clinical Review
Omuro, A. (2013) · JAMA · doi:10.1001/jama.2013.280319 · Cited by 2,301
Wang, Q., Hu, B., Hu, X., Kim, H., Squatrito, M., Scarpace, L., deCarvalho, A. C., Lyu, S., Li, P., Li, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.003 · Cited by 1,995
Self-citationIntratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Sottoriva, A., Spiteri, I., Piccirillo, S. G. M., Touloumis, A., Collins, V. P., Marioni, J. C., Curtis, C., Watts, C., & Tavaré, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219747110 · Cited by 1,737
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432
Self-citationBrem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,389
Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., Wang, A. C., Ellingson, B. M., Rytlewski, J. A., Sanders, C. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0337-7 · Cited by 1,382
Self-citationClinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Brandsma, D., Stalpers, L., Taal, W., Sminia, P., & van den Bent, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70125-6 · Cited by 1,121
Lomustine and Bevacizumab in Progressive Glioblastoma
Wick, W., Gorlia, T., Bendszus, M., Taphoorn, M., Sahm, F., Harting, I., Brandes, A. A., Taal, W., Domont, J., Idbaih, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707358 · Cited by 970
Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862
Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., & Ryan, J. L. (1997) · PubMed · Cited by 820
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N., Bolognesi, D. P., Friedman, A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716435 · Cited by 815
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
Self-citationTaal, W., Oosterkamp, H. M., Walenkamp, A. M. E., Dubbink, H. J., Beerepoot, L. V., Hanse, M. C. J., Buter, J., Honkoop, A. H., Boerman, D., de Vos, F. Y. F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70314-6 · Cited by 759
Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue
Gerdes, M. J., Sevinsky, C. J., Sood, A., Adak, S., Bello, M. O., Bordwell, A., Can, A., Corwin, A., Dinn, S., Filkins, R. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300136110 · Cited by 724
Lang, F. F., Conrad, C., Gomez-Manzano, C., Yung, W. K. A., Sawaya, R., Weinberg, J. S., Prabhu, S. S., Rao, G., Fuller, G. N., Aldape, K. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.8219 · Cited by 711
Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
Nathanson, D. A., Gini, B., Mottahedeh, J., Visnyei, K., Koga, T., Gomez, G., Eskin, A., Hwang, K., Wang, J., Masui, K., et al. (2014) · Science · doi:10.1126/science.1241328 · Cited by 695
Batchelor, T. T., Mulholland, P., Neyns, B., Nabors, L. B., Campone, M., Wick, A., Mason, W., Mikkelsen, T., Phuphanich, S., Ashby, L. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2464 · Cited by 614
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
Ricklefs, F. L., Alayo, Q., Krenzlin, H., Mahmoud, A. B., Speranza, M. C., Nakashima, H., Hayes, J. L., Lee, K., Balaj, L., Passaro, C., et al. (2018) · Science Advances · doi:10.1126/sciadv.aar2766 · Cited by 610
Self-citationMicallef, M. J., Ohtsuki, T., Kohno, K., Tanabe, F., Ushio, S., Namba, M., Tanimoto, T., Torigoe, K., Fujii, M., Ikeda, M., et al. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260736 · Cited by 597
Atkins, M. B., Robertson, M. J., Gordon, M. S., Lotze, M. T., DeCoste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D. J., Garzone, P. D., et al. (1997) · PubMed · Cited by 583
Wick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L. M., Mason, W., Weller, M., Hong, S., Musib, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 525
Interleukin 12: still a promising candidate for tumor immunotherapy?
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495
Zhang, L., Morgan, R. A., Beane, J. D., Zheng, Z., Dudley, M. E., Kassim, S. H., Nahvi, A. V., Ngo, L. T., Sherry, R. M., Phan, G. Q., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2085 · Cited by 444
Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Self-citationKmiecik, J., Poli, A., Brons, N. H. C., Waha, A., Eide, G. E., Enger, P. Ø., Zimmer, J., & Chekenya, M. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.08.013 · Cited by 389
Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity
Meyer, M., Reimand, J., Lan, X., Head, R., Zhu, X., Kushida, M., Bayani, J., Pressey, J. C., Lionel, A. C., Clarke, I. D., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320611111 · Cited by 382
Pseudoprogression and pseudoresponse in the treatment of gliomas
Brandsma, D., & van den Bent, M. J. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328332363e · Cited by 378
Immunosuppressive mechanisms in glioblastoma: Fig. 1.
Nduom, E. K., Weller, M., & Heimberger, A. B. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov151 · Cited by 348
Sangro, B., Mazzolini, G., Ruiz, J., Herraiz, M., Quiroga, J., Herrero, I., Benito, A., Larrache, J., Pueyo, J., Subtil, J. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.059 · Cited by 320
Brain Tumor Microenvironment and Host State: Implications for Immunotherapy
Tomaszewski, W., Sanchez-Perez, L., Gajewski, T. F., & Sampson, J. H. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1627 · Cited by 319
T-cell Dysfunction in Glioblastoma: Applying a New Framework
Woroniecka, K. I., Rhodin, K. E., Chongsathidkiet, P., Keith, K. A., & Fecci, P. E. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0047 · Cited by 315
Curtsinger, J. M., Johnson, C. M., & Mescher, M. F. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.10.5165 · Cited by 287
Brandes, A. A., Carpentier, A. F., Kesari, S., Sepulveda-Sanchez, J. M., Wheeler, H. R., Chinot, O., Cher, L., Steinbach, J. P., Capper, D., Specenier, P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now009 · Cited by 273
Suchorska, B., Weller, M., Tabatabai, G., Senft, C., Hau, P., Sabel, M. C., Herrlinger, U., Ketter, R., Schlegel, U., Marosi, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov326 · Cited by 254
Ellingson, B. M., Chung, C., Pope, W. B., Boxerman, J. L., & Kaufmann, T. J. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2375-2 · Cited by 246
Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier
Da Ros, M., De Gregorio, V., Iorio, A. L., Giunti, L., Guidi, M., De Martino, M., Genitori, L., & Sardi, I. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102879 · Cited by 223
The Toxicology of Interleukin-12: A Review
Car, B. D., Eng, V. M., Lipman, J. M., & Anderson, T. D. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700112 · Cited by 220
Rosewell Shaw, A., Porter, C. E., Watanabe, N., Tanoue, K., Sikora, A., Gottschalk, S., Brenner, M. K., & Suzuki, M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.010 · Cited by 219
Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection
vom Berg, J., Vrohlings, M., Haller, S., Haimovici, A., Kulig, P., Sledzinska, A., Weller, M., & Becher, B. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130678 · Cited by 213
The Controversial Role of Microglia in Malignant Gliomas
Wei, J., Gabrusiewicz, K., & Heimberger, A. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/285246 · Cited by 207
The Evidence of Glioblastoma Heterogeneity
Soeda, A., Hara, A., Kunisada, T., Yoshimura, S.-I., Iwama, T., & Park, D. M. (2015) · Scientific Reports · doi:10.1038/srep07979 · Cited by 205
Advances and challenges in the treatment of glioblastoma: a clinician's perspective.
Mrugała, M. M. (2013) · PubMed · Cited by 203
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma
Cloughesy, T. F., Landolfi, J., Hogan, D. J., Bloomfield, S., Carter, B., Chen, C. C., Elder, J. B., Kalkanis, S. N., Kesari, S., Lai, A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9784 · Cited by 195
Mazzolini, G., Alfaro, C., Sangro, B., Feijoó, E., Ruiz, J., Benito, A., Tirapu, I., Arina, A., Sola, J., Herraiz, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.463 · Cited by 179
Wheeler, L. A., Manzanera, A. G., Bell, S. D., Cavaliere, R., McGregor, J. M., Grecula, J. C., Newton, H. B., Lo, S. S., Badie, B., Portnow, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now002 · Cited by 172
Self-citationRandomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
Field, K. M., Simes, J., Nowak, A. K., Cher, L., Wheeler, H., Hovey, E. J., Brown, C. S. B., Barnes, E. H., Sawkins, K., Livingstone, A., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov104 · Cited by 160
SINGLE CELL DERIVED CLONAL ANALYSIS OF HUMAN GLIOBLASTOMA LINKS FUNCTIONAL AND GENOMIC HETEROGENEITY
Dirks, P. B., Meyer, M., Reimand, J., Lan, X., Head, R., Zhu, X., Kushida, M. M., Bayani, J., Pressey, J. C., Lionel, A. C., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou206.51 · Cited by 133
Salvage therapy with single agent bevacizumab for recurrent glioblastoma
Chamberlain, M. C., & Johnston, S. K. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9957-6 · Cited by 124
A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma
Chiocca, E. A., Smith, K., McKinney, B., Palmer, C. A., Rosenfeld, S. A., Lillehei, K. O., Hamilton, A. J., DeMasters, B. K., Judy, K. D., & Kirn, D. H. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300396 · Cited by 119
Self-citationBarrett, J. A., Cai, H., Miao, J., Khare, P. D., Gonzalez, P., Dalsing-Hernandez, J. E., Sharma, G., Chan, T., Cooper, L. J. N., & Lebel, F. M. (2018) · Cancer Gene Therapy · doi:10.1038/s41417-018-0019-0 · Cited by 101
Self-citationViral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?
Chiocca, E. A., Nassiri, F., Wang, J. Q., Peruzzi, P., & Zadeh, G. M. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy170 · Cited by 91
Self-citationBrandes, A. A., Finocchiaro, G., Zagonel, V., Reni, M., Caserta, C., Fabi, A., Clavarezza, M., Maiello, E., Eoli, M., Lombardi, G., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now035 · Cited by 86
Outcomes after second surgery for recurrent glioblastoma: a retrospective case–control study
Wann, A., Tully, P., Barnes, E. H., Lwin, Z., Jeffree, R. L., Drummond, K. J., Gan, H. K., & Khasraw, M. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2731-2 · Cited by 75
Interleukin-12 as an Adjuvant for Cancer Immunotherapy
Rodolfo, M., & Colombo, M. P. (1999) · Methods · doi:10.1006/meth.1999.0836 · Cited by 72
Treating recurrent glioblastoma: an update
Kamiya-Matsuoka, C., & Gilbert, M. R. (2015) · CNS Oncology · doi:10.2217/cns.14.55 · Cited by 72
Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism
Sood, A., Miller, A. M., Brogi, E., Sui, Y., Armenia, J., McDonough, E. M., Santamaría-Pang, A., Carlin, S., Stamper, A. R., Campos, C., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87030 · Cited by 57
Microenvironmental Clues for Glioma Immunotherapy
Platten, M., Ochs, K., Lemke, D., Opitz, C. A., & Wick, W. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0440-1 · Cited by 53
Pseudoprogression after glioma therapy: an update
Galldiks, N., Köcher, M., & Langen, K. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1375405 · Cited by 52
Molecular responses to immune checkpoint blockade in glioblastoma
Ito, H., Nakashima, H., & Chiocca, E. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0385-7 · Cited by 46
Self-citationImmunotherapy for glioblastoma: on the sidelines or in the game?
Reardon, D. A., Wucherpfennig, K. W., & Chiocca, E. A. (2017) · PubMed · Cited by 44
Self-citationConditional interleukin-12 gene therapy promotes safe and effective antitumor immunity
Komita, H., Zhao, X., Katakam, A. K., Kumar, P., Kawabe, M., Okada, H., Braughler, J. M., & Storkus, W. J. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.33 · Cited by 39
Immunomodulation for glioblastoma
Reardon, D. A., Wen, P. Y., Wucherpfennig, K. W., & Sampson, J. H. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000451 · Cited by 26
Self-citationApplied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma
Johanns, T. M., & Dunn, G. P. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000247 · Cited by 20
Cai, H., Sun, L., Miao, J., Krishman, S., Lebel, F. M., & Barrett, J. A. (2016) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.287 · Cited by 15
Self-citationLotze, M. T. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb52649.x · Cited by 8
Cited by
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Self-citationClinical relevance of tumour-associated macrophages
Pittet, M. J., Michielin, O., & Migliorini, D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00620-6 · Cited by 731
de Almeida, L. G. N., Thode, H., Eslambolchi, Y., Chopra, S., Young, D., Gill, S., Devel, L., & Dufour, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000349 · Cited by 535
Localized Interleukin-12 for Cancer Immunotherapy
Nguyen, K. G., Vrabel, M. R., Mantooth, S. M., Hopkins, J. J., Wagner, E. S., Gabaldon, T. A., & Zaharoff, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.575597 · Cited by 431
Immunotherapy for glioblastoma: current state, challenges, and future perspectives
Liu, Y., Zhou, F., Ali, H., Lathia, J. D., & Chen, P. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01226-x · Cited by 336
Metadata
- Authors
- Chiocca, E. A., Yu, J. S., Lukas, R. V., Solomon, I. H., Ligon, K. L., Nakashima, H., Triggs, D. A., Reardon, D. A., Wen, P., Stopa, B. M., Naik, A., Rudnick, J., Hu, J. L., Kumthekar, P., Yamini, B., Buck, J. Y., Demars, N., Barrett, J. A., Gelb, A. B., Zhou, J., Lebel, F., & Cooper, L. J. N.
- Venue
- Science Translational Medicine
- Published
- 2019-08-14
- Volume
- 11
- Issue
- 505
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2968965260
- Cited by
- 263
- References
- 71
- FWCI
- 15.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.